Beijing PM Bio

Beijing Pu-M Bio-Tech (Pu-M Bio) is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to developing next-generation multi-specific antibody therapies for cancer. The company leverages its proprietary PM-Body technology platform to design and engineer bispecific antibodies and bifunctional fusion proteins that target complex immune evasion mechanisms. Its lead candidate, PM1001, is a PD-L1/TGF-beta bifunctional fusion protein currently in Phase 2 clinical trials for various solid tumors. Other key programs include PM1003, a PD-1/VEGF bispecific antibody, and PM1009, a Claudin 18.2/CD3 bispecific antibody. Pu-M Bio focuses on addressing unmet medical needs in oncology by creating innovative biologics with enhanced efficacy and safety profiles.